Cellectis S.A. - American Depositary Shares (CLLS) closed at $1.04 on November 2, 2026, down 4.2% from the previous close, on volume of 22,007 shares (30-day average 96,468).
Data as of November 2, 2026.
2-Nov-2026
Globe Newswire (Tue, 27-Oct 3:15 AM ET)
Globe Newswire (Thu, 15-Oct 11:00 AM ET)
PRNewswire (Thu, 15-Oct 10:02 AM ET)
Globe Newswire (Thu, 15-Oct 9:00 AM ET)
Globe Newswire (Wed, 14-Oct 4:54 PM ET)
CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law
Business Wire (Sat, 19-Sep 7:31 PM ET)
Cellectis R&D Day Shines Spotlight on Phase 2 Strategy for Lasme-cel in r/r B-ALL
Market Chameleon (Thu, 16-Oct 6:39 AM ET)
Cellectis Showcases Pivotal Phase 2 Strategy for lasme-cel in r/r B-ALL at R&D Day
Market Chameleon (Thu, 16-Oct 5:46 AM ET)
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Cellectis S.A. - American Depositary Shares trades on the NASDAQ stock market under the symbol CLLS.
As of November 2, 2026, CLLS stock price declined to $1.03 with 22,007 million shares trading.
CLLS has a beta of 2.02, meaning it tends to be more sensitive to market movements. CLLS has a correlation of 0.06 to the broad based SPY ETF.
CLLS has a market cap of $104.22 million. This is considered a Micro Cap stock.
Last quarter Cellectis S.A. - American Depositary Shares reported $7 million in Revenue and -$.19 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.07.
In the last 3 years, CLLS traded as high as $5.48 and as low as $.88.
The top ETF exchange traded funds that CLLS belongs to (by Net Assets): IBB.
CLLS has underperformed the market in the last year with a return of -70.3%, while the SPY ETF gained +11.7%. In the last 3 month period, CLLS fell short of the market, returning -63.7%, while SPY returned +1.7%. However, in the most recent 2 weeks CLLS has outperformed the stock market by returning -0.5%, while SPY returned -1.5%.
CLLS support price is $1.00 and resistance is $1.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLLS shares will trade within this expected range on the day.
